Sanara MedTech Inc. (SMTI) AI Stock Analysis

Sanara MedTech Inc., headquartered in Fort Worth, Texas, develops, markets, and distributes advanced wound and skin care products throughout the United States. It serves healthcare settings such as physicians, hospitals, clinics, and post-acute care facilities. The company's portfolio features CellerateRX Surgical Activated Collagen in powder and gel forms, which is used across surgical specialties. It also distributes Biakos antimicrobial cleansers and wound gels designed to target mature biofilm microbes and planktonic microbes, as well as HYCOL Hydrolyzed Collagen for managing complex ulcers. In addition, Sanara develops wound care devices like FORTIFY TRG and FORTIFY FLOWABLE using freeze-dried extracellular matrix technology.

Annual revenue grew from $24.1M in FY2021 to $103.1M in FY2025, achieving a 5-year CAGR of 45.9%. Over that period, gross margin stayed near or above 86.1%, reaching 90.1% in FY2025. Operating margin turned positive at 8.9% in FY2025 after coming in at -7.7% in FY2024. However, net income fell to -$37.6M in FY2025 from -$9.7M in FY2024, resulting in diluted EPS of -$4.35. For the trailing twelve months ended June 30, 2026, revenue totaled $109.8M with an operating margin of 6.3% and a net profit margin of -29.1%. Quarterly revenue growth for the period ended June 30, 2026, was 9.0% year-over-year.

As of June 30, 2026, Sanara MedTech held $15.4M in cash and short-term investments against total debt of $48.5M, resulting in net debt of $33.1M. Shareholders' equity was $7.9M, giving the company a debt-to-equity ratio of 6.11 and a current ratio of 2.58. Total assets were $69.1M. In FY2025, operating cash flow turned positive at $6.8M, supporting capital expenditures of $4.6M and yielding free cash flow of $2.2M. Over the past five years, the company's share count increased by 15.2%.

At $33.16 per share, Sanara MedTech has a market capitalization of $304.7M and an enterprise value of $356.1M. SMTI trades at a forward P/E of 217.4x and an EV/EBITDA of 36.0x, both above the US-listed Healthcare median peers of 17.3x and 12.0x, respectively. Its price-to-sales ratio is 2.8x compared to the peer median of 4.1x, while price-to-book stands at 40.7x. Over the past year, SMTI shares gained 13.2%, trailing the S&P 500 (SPY) return of 16.8%, but have gained 42.0% year-to-date.

Wall Street coverage includes 3 Hold ratings, with 0 Buy and 0 Sell ratings. The mean price target is $35.00, representing a 5.5% premium to the last close of $33.16. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $0.20 on revenue of $116.6M. For FY2027, 1 analyst projects revenue of $133.2M, representing 14.2% growth, and EPS of $0.54. Over the last four quarters, the company beat EPS estimates 1 time. The next earnings date is November 11, 2026.

This page is an AI-written research summary of Sanara MedTech Inc. (SMTI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SMTI income statement, SMTI balance sheet, SMTI key metrics, SMTI analyst forecast, SMTI chart. See the SMTI stock overview for the latest quote and news.